(RTTNews) - Nymox Pharmaceutical Corp. (NYMX: News ) Monday said that its multi-center U.S. Phase 2 studies of NX-1207 indicated positive data from responder analysis, the new clinical trial for benign prostatic hyperplasia or BPH.

The St. Laurent, Canada-based company said that BPH causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems, and can lead to other complications.

The study was conducted on early responders who reported 6 point or better improvement in BPH Symptom Score improvement within a month of treatment.

Post-treatment, on an average of 14 months there were over 4.3 times as many NX-1207 early responders who had maintained the symptom score and further did not require any kind of BPH treatment as compared to placebo controls.

The mean improvement in symptom score at 3 months for all patients who received a single 2.5 mg dose of NX-1207 was 10.5 points; the median improvement was 10 points, said Nymox

Patients treated with NX-1207 did not report any of the sexual or low blood pressure side effects.
The company said that the currently approved BPH medications, NX-1207 treatment does not require the patient to take pills daily for the rest of his life and the dose is being used in the ongoing U.S. Phase 3 trials of NX-1207.

NX-1207 is administered by a urologist in an office procedure that takes only a few minutes and involves little or no pain or discomfort.

Statistically, worldwide more than 100 million men are estimated to suffer from BPH symptoms, noted Nymox

NYMX last traded at $4.86, down $0.10 or 1.21% on the Nasdaq.

To receive FREE breaking news email alerts for Nymox Pharmaceutical Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com